Strong revenue growth at Dechra

Related Companies

Related Indices

Related Sectors

News for Spread Betters

PreviousPrevious
NextNext

There's a new Investor Edition of CMC Markets' spread betting platform... and it's exclusive to DigitalLook.com users...

Get full details about Marketmaker:Investor Edition here. Advertisement

Date: Tuesday 08 Jul 2008

LONDON (ShareCast) - Veterinary pharmaceuticals distributor Dechra has seen strong revenue growth in the last year, in line with management expectations.

The group expects revenue in the year to 30 June 2008 to be some 20% ahead of the previous year, with strong performance from the company’s key products, Vetoryl and Felimazole, as they achieve further penetration in Europe.

Initial revenues from recently launched products Domidine, Sedator, Thyroxyl and Ovuplant have been in line with expectations.

The integration of the VetXX acquisition has gone well with the full delivery of the expected cost synergies.

The services division continues to operate in a buoyant but competitive market; National Veterinary Services retained its leading position, with a market share exceeding 44%.

“During the financial year the group has made exceptional strategic progress with the acquisition of VetXX significantly strengthening our pharmaceuticals division,” the group said.

“With this acquisition now integrated, the robust performance of our core businesses and an exciting pipeline of novel and generic products, we look forward to the future with confidence,” it added.

Digital Look have been voted
"Best Research and Information Provider"

4th Floor, Bankside House, 107 Leadenhall Street, London EC3A 4AF.
Registered in England and Wales (registered no. 3678570).